Price Change to Note: Curis, Inc. on Focus After Raising In Today’s Session

Price Change to Note: Curis, Inc. on Focus After Raising In Today's Session

The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! About 193,521 shares traded hands. Curis, Inc. (NASDAQ:CRIS) has risen 50.62% since April 5, 2016 and is uptrending. It has outperformed by 48.66% the S&P500.
The move comes after 6 months positive chart setup for the $342.47M company. It was reported on Nov, 7 by We have $4.02 PT which if reached, will make NASDAQ:CRIS worth $181.51 million more.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on November, 14. They expect $-0.11 EPS, down 175.00% or $0.07 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Curis, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. The firm earned “Hold” rating on Tuesday, September 1 by Zacks. TH Capital maintained Curis, Inc. (NASDAQ:CRIS) rating on Monday, November 9. TH Capital has “Buy” rating and $5 price target. The rating was maintained by Roth Capital with “Buy” on Monday, November 9. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 11.

According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”

Insitutional Activity: The institutional sentiment increased to 1.78 in Q2 2016. Its up 0.88, from 0.9 in 2016Q1. The ratio increased, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
The Florida-based Raymond James Fincl Services has invested 0% in Curis, Inc. (NASDAQ:CRIS). Cornerstone Holding Llc, a New York-based fund reported 24,100 shares. Comml Bank Of America Corporation De, a North Carolina-based fund reported 29,930 shares. Blackrock Advisors Lc, a Delaware-based fund reported 51,005 shares. The New York-based Springbok Mngmt Limited Liability Co has invested 0% in Curis, Inc. (NASDAQ:CRIS). Group last reported 0% of its portfolio in the stock. Metropolitan Life Ins Ny holds 0% or 93,379 shares in its portfolio. Baker Bros L P has 2.00 million shares for 0.03% of their US portfolio. Geode Capital Mngmt Ltd Llc has 782,199 shares for 0% of their US portfolio. Citigroup Inc accumulated 0% or 26,659 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in Curis, Inc. (NASDAQ:CRIS). The New York-based Alliancebernstein L P has invested 0% in Curis, Inc. (NASDAQ:CRIS). Amalgamated Bank & Trust has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Fmr Lc holds 0% or 15.92M shares in its portfolio. Salem Investment Counselors Inc accumulated 0% or 10,000 shares.

Insider Transactions: Since May 26, 2016, the stock had 0 buys, and 2 sales for $51,750 net activity. Shares for $25,350 were sold by GREENACRE MARTYN D on Friday, May 27. $26,400 worth of Curis, Inc. (NASDAQ:CRIS) was sold by KAITIN KENNETH I on Thursday, May 26.

CRIS Company Profile

Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment